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Abstract. The Hedgehog/Patched signaling pathway plays a
prominent role during mammalian development but it is also
involved in oncogenic transformation. We investigated the
methylation status of the Patched promotor in a set of baso-
cellular carcinomas of the skin and ovarian tumors as an
alternative to mutational causes of the pathway deregulation.
Our aim was to define a possible role of genetic and/or epi-
genetic mechanisms of Hedgehog/Patched signal transduction
in the development of these tumors. Bisulfite-converted
DNA from tumors and from matched healthy tissue was
amplified by a specific PCR and the CpG-rich regions of the
Patched promoter were sequenced. Two promoter regions
showed statistically significant hypermethylation compared
to healthy controls in ovarian tumors; more significantly in
the region in the vicinity of Gli1-binding sites and less
significantly in the region containing the ATG codon. But, in
basocellular carcinomas of the skin we observed no difference
in methylation, suggesting different mechanisms of neoplasia
in these tumors.
Introduction
Research on the Hedgehog/Patched pathway involvement in
a number of common human cancers (1) relies heavily on
investigations of the pathway malfunctioning in less frequent
or barely malignant neoplasia related to Gorlin syndrome. In
this manuscript we present the results of an investigation aimed
at evaluating the potential of Patched hypermethylation as an
alternative to mutational causes of the pathway deregulation
in different tumors, indicating two unrelated events. The
choice of tumors came from previous investigations on
tumors involved in Gorlin syndrome.
Gorlin syndrome or Basal Cell Nevus Syndrome (BCNS)
is a rare heritable autosomal dominant disorder characterized
by developmental malformations and a predisposition to
basocellular carcinoma (BCC), odontogenic keratocysts
(OKCs), ovarian fibroma, medulloblastoma and other
neoplasia. Frequent loss of heterozygosity (LOH) at the
9q22.3 locus in BCNS neoplastic formations facilitated the
cloning of the Patched (PTCH) gene (2) a tumor suppressor
(also known as PTCH1), and a human homologue of the
Drosophila gene Patched. It also led to the explanation that
the syndrome is caused by constitutional hemizygous
alteration of the PTCH gene, confirming Knudson's two-hit
hypothesis (3) that total inactivation of the gene (enabling
neoplastic proliferation) can be more easily achieved by a
somatic hit on the remaining wild-type allele in BCNS than
by inactivation of both alleles in the general population.
Subsequent investigations of typical BCNS neoplasia
in the general population, BCC in particular, revealed that
they could also be caused by activating mutations of the
Smoothened gene (SMO), as an alternative to PTCH
inactivation. This contributed to a further understanding of
the Hedgehog/Patched (HH/PTC) pathway, also called the
HH/GLI pathway, or SHH/PTCH pathway in mammals, due
to the prevailing role of the Sonic Hedgehog (SHH)
mammalian homologue of HH. This pathway has important
functions during development, when its activation is
normally initiated by the secreted protein Shh, a ligand that
binds to its trans-membrane receptor Ptch. When this
happens, Ptch relieves its repression of the co-receptor Smo,
also a membrane protein. Smo then activates a downstream
cascade that leads to the translocation of the active form of
the transcription factor Gli1 to the nucleus (4). Many of Gli1
targets are associated with cell proliferation, indicating that
this proto-oncogene can induce cell transformation through
multiple pathways (1). In addition, PTCH itself is also
included among the Gli targets, and auto-regulation of the
SHH/PTCH pathway is normally achieved by increased
production of Ptch protein.
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The role of PTCH in maintaining and restoring the
repression of Smo crucially depends on the ability of the
gene to produce functional Ptch protein and to increase
production of Ptch protein after the pathway activation.
Various PTCH mutations causing C-terminal truncation of
Ptch protein, after which the latter can no longer repress
Smo, are well-documented mechanisms of the SHH/PTCH
pathway deregulation (5). Whereas Ptch haploinsufficiency
caused by the constitutive mutations of one PTCH allele in
BCNS is hypothesized to be the likely cause for develop-
mental malformations in the syndrome, tumors typical of
BCNS generally require full loss of the PTCH regulatory
function (unless they are caused by alterations of other
pathway genes). In many of these tumors, Ptch disabling
mutations have been found on both alleles, but in others no
alterations in PTCH coding sequence have been seen despite
indications that the gene is involved in their development
(such as the LOH at the 9q22.3 locus). Therefore, the interest
of research has been expanded to the PTCH promoter region
as another potentially weak spot, where two Gli-binding sites
mediate downstream pathway regulation through PTCH
expression.
In our previous investigations of BCNS-related disorders,
OKCs in particular, we detected LOH at the PTCH locus in
dentigerous cysts as well, which led us to hypothesize that
the PTCH gene may be involved in developmental cysts in
general (6). The possibility that such mild disorders with low
incidence in the general population may be related to the
PTCH gene, but not associated with BCNS, can perhaps be
explained by the very low prevalence of this syndrome.
Due to similar expression levels of pathway genes, we
have included ovarian dermoids in our more recent investi-
gations of ovarian fibroma (7). The latter are very strongly
associated with BCNS and therefore expected to be largely
caused by PTCH alterations: the incidence of ovarian fibroma
in the syndrome patients is several times greater than in the
general female population, and this relative increase is
comparable to or greater than that of BCCs, the most common
syndrome neoplasia.
Although increased expression levels of several SHH/
PTCH pathway genes in a number of tumors obtained from
the general population have provided additional indication of
the pathway involvement in both ovarian fibroma and
dermoids (8), direct sequencing of PTCH exons revealed no
mutations. Since it would be too unlikely that the PTCH gene
is not involved at least in some fibroma, we have proceeded
to analyze the PTCH promoter, focusing on the methylation of
the region. In order to not exclude other tumors where PTCH
mutations are very common, we examined BCCs in the same
way. Inactivating mutations of PTCH in sporadic BCCs and,
consequently, different levels of expression of members of
the Hh-Gli signaling pathway have been reported (9), but the
PTCH promoter status has not yet been observed.
Changes in the patterns of DNA methylation have been
correlated with a number of different processes in mammals
(10). However, more relevant for this investigation is the
phenomenon of hypermethylation of the gene promoter (11).
It has been established that CpG island methylation in the
promoter region can inactivate tumor suppressor genes in
human cancers, and that such CpG sites often show an
increased mutation rate (12,13). Also, promoter hyper-
methylation of several tumor suppressor genes has already
been reported in primary ovarian carcinoma (14). 
We examined the methylation status of the PTCH
promoter in different set of tumors; basocellular carcinomas,
ovarian fibromas and ovarian dermoids. 
Materials and methods
Samples and procedures. All samples were obtained from the
Department of Obstetrics and Gynecology, School of
Medicine, University of Zagreb; Clinical Hospital Petrova,
Zagreb; and from the Department of Maxillofacial Surgery,
Clinical Hospital Osijek, Osijek, Croatia. During surgery the
samples were excised for pathohistological examination (by a
pathologist), and for molecular analysis. For molecular
analysis we used cyst lining in the case of ovarian dermoids,
and stromal tissue in the case of ovarian fibroma and baso-
cellular carcinomas of the skin. Both dermoids and fibroma
can be found anywhere in the body, but since all our samples
were taken from ovaries, stromal tissue from healthy ovaries
was used as a control for both tumor types. As a control for
basocellular carcinomas we used healthy skin samples.
Samples were dissected with a scalpel and conserved in
culture medium or in RNA Later solution for DNA and RNA
isolation. The samples were stripped of identifiers, could not
be traced back to patients and were collected with consideration
to all necessary ethical and legal requirements.
The tissue samples were denoted as follows: F, ovarian
fibroma; D, ovarian dermoids; NO, normal ovaries; B, baso-
cellular carcinomas of the skin; and NS, normal skin. Additional
labels ‘a’ and ‘b’ were introduced when two different samples
were taken from the same person (e.g. NO1a and NO1b).
Methylation of a promoter sequence was determined
using bisulfite genomic sequencing method (15) which is
based on chemical alteration of DNA where sodium bisulfite
converts unmethylated cytosines into uracils, but 5-methyl-
cytosine remains unaltered.
Before bisulfite conversion, genomic DNA was cut with
restriction enzyme SalI, because it does not cut within the
PTCH promoter region, neither the original sequence nor the
converted one. After bisulfite conversion, the CpG-rich region
of interest was amplified by specifically designed primers.
DNA extraction. DNA from all samples was digested in
buffer (0.9% Tween-20, 0.9% Triton X-100, 5 mM EDTA,
2 mM DTT, 10 mM TrisHCl pH 7.5) and proteinase K
(20 μg/ml) overnight at 55˚C and extracted by the standard
phenol-chloroform method.
Bisulfite modification. DNA (2 μg) was cut with restriction
enzyme SalI. Restriction was performed overnight at 37˚C.
The following day the volume was adjusted to a total of 90 μl,
and denatured with NaOH (final concentration, 0.3 M) for
20 min at 42˚C. A bisulfite and hydroquinone solution was
freshly prepared (2.5 M sodium metabisulfite, 0.001 M
hydroquinone, and 0.4 M NaOH), dissolved without vigorous
shaking and filtered through a 0.45-μm filter. This solution
(1200 μl) was added directly to the denatured DNA and
incubated overnight at 55˚C in the dark.
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DNA was then purified using Promega Wizard DNA
purification kit (Madison, WI, USA), desulfonated with
NaOH (final concentration, 0.3 M) at 37˚C for 20 min,
neutralized and precipitated overnight with ammonium
acetate and carrier tRNA and ethanol. Converted DNA was
ready for further PCR amplification. 
Conversion efficiency. We verified the conversion efficiency
by examining the conversion of non-CpG cytosines into
uraciles. The original protocol suggested 4 h of incubation,
but it gave 41% non-converted cytosines. Doubling the
incubation to 8 h reduced the non-converted cytosines to
36%. Finally, overnight incubation (16-18 h) provided
adequate efficiency, with at most 8% of the non-CpG
cytosines not completely converted to thymines (and these
were located mostly at the ends of sequences). This 8%
conversion inefficiency limit for non-CpG cytosines was
maintained for all samples, both normal and tumor (>72
sequences), and for most of the samples the conversion
inefficiency limit was considerably lower (~4-5%). Sequences
with non-CpG conversion inefficiency >8% were discarded.
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Figure 1. Position of the Patched gene promoter and the first two exons.
Alternative forms of exon 1 (a, b, c, d, and e) are marked according to
Nagao et al (16), and in parentheses according to Agren et al (4). The
promoter is located in the 5' region upstream of exon 1b and encompasses
whole exon 1b. It consists of a CpG-rich region of 1593 bp containing 163
CpG sites. The positions of two Gli1-binding sites, transcription start, and
ATG codon are marked. Four sets of primers were designed to amplify both
methylated and unmethylated DNA of the CpG-rich region. 
Figure 2. Hypothetical sequence of the analyzed region after bisulfite conversion in which all non-CpG cytosines were replaced with thymines, but cytosines
within the CpG sites remained as cytosines. All CpG islands are shaded; primers of the four sub-regions are indicated by forward and reverse arrows; and Gli-
binding sites are marked with circles and ATG is in a square.
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Primer design and PCR amplification. The PTCH promoter
sequence was determined according to NCBI database (Gene
ID no. 5727) and Agren et al (4). Position of the CpG island-
rich promoter region selected for analysis (-1008 to +575) is
schematically shown in Fig. 1, relative to alternative exon 1
sequences (16). It encompasses two Gli1-binding sites and
the transcription start at +1 with ATG signal at +373. Agren et al
(4) showed that only the second Gli-binding site, on position
-704 to -696, is fully functional. Details of the selected
promoter region are shown in Fig. 2, which presents the
hypothetical sequence after bisulfite conversion of all non-
CpG cytosines (they are replaced with thymines) in order to
facilitate recognition of CpGs and their methylation status.
For amplification, the promoter was divided into four sub-
regions, and 4 sets of primers were designed, avoiding CpGs
to ensure that all would be amplified, whether methylated or
not. The positions of the primers and segments that they
cover are marked in both Figs. 1 and 2. Finally, sequencing
was performed to compare the number of methylated vs.
unmethylated CpGs.
Primer sequences were as follows: PR1 forward, 5'-GTT
GTA GTT TGA GGT TAA GGT GTT TTT-3' and reverse,
5'-CTA TCA AAT AAC TTA AAT TTC TA-3'; PR2
forward, 5'-GTA GAA TTT AAG TTA TTT GAT AGT-3'
and reverse, 5'-CT CCA AAA ACT ACT ACT-3'; PR3
forward, 5'-GAG TAT AAG AAA GTA GAG TT-3' and
reverse, 5'-CCT TCC ATT ACC ACA TTA C-3'; PR4
forward, 5'-GTA ATG TGG TAA TGG AAG G-3' and
reverse, 5'-CCT TAA AAA TCT ACT CCA AAA-3'. Primer
pair PR1 forward-reverse produces a 422-bp-sized product
containing Gli binding sites, and it is denoted as region 1,
position from -1008 to -586. Primer pair PR2 forward-
reverse produces a 360-bp segment (region 2, -610 to -250),
whereas primer pair PR3 forward-reverse produces a 473-bp-
sized product (region 3, -338 to +135). Primer pair PR4
forward-reverse amplifies a 449-bp-sized segment containing
the start codon ATG (region 4, +126 to +575). 
Converted DNA (1 μl) was used in a 25-μl PCR reaction,
with AmpliTaq Gold enzyme at the following conditions:
95˚C for 10 min, and 45 times 95˚C for 1 min, 50˚C for 2 min,
70˚C for 2 min and then 68˚C for 10 min. The PCR product
(1 μl) was used as a template for a second amplification in a
50-μl PCR reaction, with the same cycling conditions. The
PCR product was excised from the 1% agarose gel and
purified for the next step (Qiagen Gel extraction kit). 
Subcloning of PCR fragments. Amplified PCR fragments
were subcloned by the method of Marchuk et al (18) using
plasmid vector pBluescript SK+ (Stratagene, Heidelberg,
Germany) and transformed into host E. coli XL1 Blue
(Stratagene) for propagation. Plasmid DNA from positive
clones was sequenced.
Sequencing. All samples were sequenced by the dideoxy
method (17) using BigDye® chemistry with Terminator v.1.1
kit and analyzed on ABI PRISM 310 genetic analyser using
DNA sequencing analysis software version 5.1. (Applied
Biosystems, Foster City, CA, USA).
Sequences were analyzed using the BioEdit program.
Each CpG site was numbered, examined and determined as:
methylated (only C present), heterozygous (both C and T
present; one strand was methylated and the other was not), or
unmethylated (only T present). Fig. 3 shows the sequence
analysis of methylated, unmethylated and partly methylated
(heterozygous) samples.
All samples were directly sequenced from a PCR product
(Fig. 4A), and for each group of samples at least two PCR
products were subcloned into bacterial plasmid and then each
colony was sequenced separately (Fig. 4B and C). By parallel
checking it was clearly evident when one of the alleles was
methylated (Fig. 4B), or unmethylated (Fig. 4C). 
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Figure 3. Sequence analysis: unmethylated section of NO 2a (A),
methylated section of F1 (B), and partly methylated (heterozygous) section
of D4 (C). The same CpG site is circled in red in all three pictures and
corresponds to CpG site number 13 in the sequence.
Figure 4. Sequence of a heterozygous sample D3 after direct sequencing of a
PCR product (A), and sequences of the same sample obtained after the
subcloning of PCR products into bacterial plasmid and sequencing of
plasmid DNA from each colony separately (B and C). It is clearly evident
that one of the alleles is methylated (B), and the other unmethylated (C).
The CpG sites shown are 7-12. 
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Screening difficulties. We attempted to analyze 50 different
samples. The analysis was partly successful for 44 samples
(Fig. 5): of 10 fibroma tissues, 9 were successfully sequenced
(4 for region 1, 6 for region 2, and 6 for region 4); of 12
dermoids, 7 were successful (4 for region 1, 6 for region 2,
and 4 for region 4); of 15 normal ovary samples, 7 had
readable sequences (6 for region 1, 3 for region 2, and 2 for
region 4); of 11 basocellular carcinomas of the skin, 7 were
successful for region 1, 4 for region 2 and 6 for region 4; and
of the 10 normal skin samples, 4 were successful for region
1, 3 for region 2 and 7 for region 4.
Expression analysis. RNA was isolated from basocellular
carcinoma tissue or healthy skin tissue using Trizol reagent
(Invitrogen), and additionally purified using High Pure RNA
isolation kit (Roche). RNA was reverse transcribed using
TaqMan reverse transcription kit (Roche). PCR was performed
using the following primers: Arp forward, 5'-GGCACCAT
TGAAATCCTGAGTGATGTG-3' and reverse, 5'-TTGCG
GACACCCTCCAGGAAGC-3'; Ptch forward, 5'-TCCTCG
TGTGCGCTGTCTTCCTTC-3' and reverse, 5'-CGTCAGAA
AGGCCAAAGCAACGTGA-3'; Gli1 forward, 5'-GCCGT
GTAAAGCTCCAGTGAACACA-3' and reverse, 5'-TCCC
ACTTTGAGAGGCCCATAGCAAG-3'. Cycling conditions
were 95˚C for 10 min; 40 times 95˚C for 30 sec, 60˚C for
45 sec, 72˚C for 45 sec; and then 72˚C for 7 min. PCR
products were separated on a 2% agarose gel and visualized
using Image Master VDS (Pharmacia Biotech.). Arp
expression was used as a housekeeping control.
Results
The methylation status of the PTCH promoter in ovarian
fibroma, ovarian dermoids, BCCs and matched healthy tissue
was investigated following bisulfite conversion, specific PCR
amplification and sequencing. The promoter region (1593-bp
long with 163 CpGs) was divided into four segments and
each of them was sequenced and analyzed separately (Figs. 1
and 2). 
Region 1 containing Gli-binding sites. The first part of the
promoter, region 1 (-1008 to -586) contains 21 CpG sites and
two Gli-binding sites (-717 to -708 and -704 to -696) located
between the 16th and the 17th CpG site. In all samples the
sequence was readable only from the 2nd CpG site on, and we
successfully analyzed and sequenced between 10 and 15
CpG sites per sample (Fig. 5).
Average methylation of region 1 in ovarian tumors was
78.88% of successfully analyzed CpGs (87.82% in fibromas
and 69.94% in dermoids), versus 0% in normal ovaries.
These two groups of samples (tumors vs. controls) showed a
statistically significant difference by the Student's t-test,
p=0.0003 for fibroma and 0.007 for dermoids (Table I).
Difference in methylation between ovarian tumors and normal
ovaries is most consistent in the vicinity of Gli-binding sites,
which are surrounded by a scattered CpG formation
extending from the 13th to the 21st site (first twelve CpGs
form a cluster far from Gli sites). 
Our analysis (Fig. 5) showed that tumors were mostly
methylated near Gli-binding sites, whereas in normal
samples there was no methylation at all on the 13th to the 16th
CpG site.
Samples F1 and F2, in which LOH was previously
detected for the 9q22.3 region (7), showed on average
moderately higher methylation than the rest of the tumors
(which had no LOH), but the difference was hardly
significant, especially because samples F3 and D1 had
similar hypermethylation (Table II).
As an additional control, two samples (‘a’ and ‘b’) were
taken from the same ovaries. Analysis of such pairs was
successful only for region 1, confirming that both samples in
each pair had either identical or reasonably similar methyl-
ation (Fig. 5).
In contrast to the ovarian and fibroma samples, the
methylation status did not differ significantly for BCC samples
in relation to healthy skin. BCCs had on average 12.82%
methylated CpGs, while healthy skin showed 8.33% methyl-
ated sites, p=0.26 (Table I). 
Region 2. Region 2 covers 21 CpGs (-610 to -250), but the
analysis was generally successful for 15 islands (the 26th to
the 40th). Average methylation of CpGs in this region was
17.95% for normal ovary samples and on average 32.05% for
ovarian and dermoid samples (39.74% for fibromas and
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Table I. Difference in methylation in tumor tissues (F, fibroma; D, dermoid; B, basocellular carcinoma) and the control as
determined by the Student's t-test.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Samples Mean (tumor tissue) Mean (control tissue) p-value
(% methylation) (% methylation)
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Region 1 F 87.82 0.00 0.0003
D 69.94 0.00 0.0070
B 12.82 8.33 0.2620
Region 2 F 39.74 17.94 0.0620
D 24.35 17.94 0.3150
B 0.00 0.00 N/A
Region 4 F 38.48 2.43 0.0110
D 23.48 2.43 0.0090
B 1.11 0.27 0.0910
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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24.36% for dermoids). Although this suggests higher
methylation in tumors, the difference was not statistically
significant [Table I, p=0.06 for fibromas and 0.31 for
dermoids (Student's t-test)]. 
Methylation was detected in neither BCC nor normal skin
samples in this region.
Region 3. This region (-338 to +135) contains a transcription
start, but it was not successfully amplified or sequenced in
the selected samples. The unsuccessful analysis may perhaps
be partly attributed to limited room for primers in the CpG
dense environment (62 sites). 
Region 4 containing ATG codon. The last part of the promoter,
region 4 (+126 to +575, with ATG at +373) contains 66 CpG
islands. In this region prevalence of methylated CpGs in
dermoids and fibromas relative to healthy ovary controls was
seen by inspection, due to the very low methylation of normal
tissue. Whereas dermoids and fibromas had on average
32.49% methylation of the successfully analyzed CpGs
(38.49% for fibroma and 23.48% for dermoids), there was
only 2.44% methylation in normal ovary samples. The
Student's t-test gave a statistically significant difference,
p=0.011 for fibromas and 0.009 for dermoids.
Both BCC and normal skin samples showed extremely
low methylation, with <2% of methylated CpGs in both
groups (1.12% for BCC samples and 0.27% for healthy skin
samples), p=0.091 (Student's t-test) (Table I).
PTCH promoter mutations. No mutations or deletions were
noted in promoter sequences during methylation analysis.
Discussion
The results of promoter methylation showed two different
patterns. In basocellular carcinomas of the skin we observed
no changes in the methylation status of the PTCH promoter
in comparison to normal skin. It has been previously
published that the whole PTCH pathway is activated in these
types of tumors, and a high mutation rate of PTCH was
observed (9,19). A large number of BCCs is associated with
alterations in PTCH signaling, which is suggested as an
option for therapeutic management of skin cancer (20).
Besides BCCs, our attention was on tumors where we have
observed activation of the pathway, but without mutations in
the PTCH gene, namely ovarian dermoids and fibromas.
These two different patterns contribute to the existence of two
independent tumor progression modes, with either promoter
hypermethylation or a mutation of tumor suppressor PTCH
as a way of pathway inactivation. While the role of PTCH in
basocellular carcinomas was observed by others through
mutational events of PTCH, SMO, SHH and even GLI1 (19),
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Table II. Patched promoter methylation data and BCC (B) expression data collated with previous results (7) of the
Hedgehog/Patched pathway gene expression in ovarian fibroma (F) and dermoids (D).
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Sample Expression Methylation (%)
–––––––––––––––––––––––––––––––– ––––––––––––––––––––––––––––––––––––––––––
ARP PTCH GLI1 Region 1 Region 2 Region 4
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
F1 + - + 92.86 28.57
F2 + - - 85.71 33.33
F3 + - + 100.00 26.00
F4 + + - 72.73 30.77 62.07
F5 + - - 69.23 77.78
F6 + - + 38.46 3.17
D1 + - + 100.00
D2 + - + 33.33 46.15
D3 + - + 75.00 46.15 20.00
D4 + + - 71.43 0.00 37.93
D5 + - + 0.00 16.00
B1 + + + 15.38 0.00 0.00
B2 + - - 20.00 0.00 0.00
B3 + + + 7.69
B4 + + + 13.33 2.63
B5 + + + 33.33 0.00
B6 + - - 0.00
B7 + + + 0.00
B8 + - + 2.17
B9 + - - 1.89
B10 + - + 0.00
B11 + - - 0.00
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Empty fields denote unsuccessful methylation readings. -, no expression; +, expression of genes in relation to the housekeeping gene Arp7.
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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the methylation as an inactivating event was not known until
now. Here we demonstrated that the promoter region of
PTCH in BCCs is not affected and therefore does not
contribute to neoplastic phenotype.
Our results revealed significantly higher methylation of
the PTCH promoter region in ovarian tumor tissues than in
normal ovarian tissue. This result was equally true for both
fibroma and dermoid samples, just as was our previous finding
of high LOH incidence at the PTCH locus in both tumor
types (8). Furthermore, the tumors with LOH (samples F1
and F2) did not appear to differ significantly in methylation
status from the others, suggesting that these two PTCH alter-
ations happen independently.
Since negative results of the mutation search in its exons
have narrowed the options of PTCH involvement in these
tumors to potential expression problems, our demonstration
of methylated CpG sites in the promoter appears to be a
viable indication of the SHH/PTCH pathway malfunctioning
in fibroma and dermoids. 
Comparison with the expression pattern of the SHH/
PTCH pathway genes in the same tumors may shed some
light on the issue. The expression data published previously
(7,8) show moderately increased activities of various pathway
genes. In particular, expression of GLI1 was not consistently
increased in all samples, whereas almost all tumors showed
some increase in both SHH and SMO expression (7,8) which
might in general be compatible with the low malignant
potential of the analyzed tumor types; although details of the
expression pattern did not quite fit into the typical model of
the pathway activation). A similar expression analysis was
performed here on BCC samples, and the results collated
with expression data for dermoids and fibromas are reviewed
in Table II. However, it should be understood that the
expression data reflect the average activity of a tumor tissue
slice, which may be lower (or different) than in the actual
proliferating cells, as suggested by the Ptch immunostaining
of dermoid lining (our previous results, 8).
Nevertheless, the compilation of our present and previous
results in Table II may contribute to delineation of the
potential role of PTCH promoter methylation in the pathway
malfunctioning. There were several cases of increased GLI
expression (F1, F3, F6, D1, D2, D3; Table II), but PTCH did
not appear to be consequently activated in either of them. The
analysis of the promoter region 1 was successful in 8 cases,
showing strong methylation, in particular of the CpGs in the
vicinity of the Gli-binding sites. This is consistent with the
hypothesis that methylation of the region prevents Gli protein
from inducing transcription of the PTCH gene. On the other
hand, methylation of the promoter region 4 (containing the
ATG codon) did not appear to have adverse effects on PTCH
activity, since the only two samples with high PTCH
expression (F4, D4) both showed very strong methylation of
this region.
Therefore, it seems likely that hypermethylation of the
Gli-binding site on the PTCH promoter (region 1) may cause
or contribute to the tumor growth in some proportion of
ovarian fibroma and dermoids, because it obstructs the
pathway auto-regulatory loop in which the activated GLI1
stimulates expression of PTCH. As for the lack of detectable
GLI1 activation in other samples, it has already been
hypothesized that proliferation of these tumors is not
necessarily always related to GLI activity (5).
Finally, it should be noted that PTCH promoter hyper-
methylation is at best only one among many potential
mechanisms of the pathway deregulation. Even when PTCH
mutations are the main cause of deregulation, the alleles of
this gene are frequently impaired by two unrelated events, as
in BCNS tumors. A straightforward generalization would
allow pathway deregulation by even less related genetic
and/or epigenetic alterations: one of them may be insufficient
synthesis of Ptch protein caused by methylated neighboring
Gli1-binding sites (perhaps only on one PTCH promoter
allele), whereas the others may include various (perhaps also
hemizygous) aberrations of any pathway gene. 
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